Evaluation of bevacizumab biosimilar on wound healing complications in patients with colorectal cancer undergoing endoscopic mucosal resection: A systematic review and meta‐analysis in anorectal medicine

• Published in: International wound journal 2024-01, Vol.21 (1), p.e14638-n/a
• Main Authors: Li, Yixi, Mei, Zhimou, Shi, Liang, Wan, Yin, Zhou, Xiaoli, Zeng, Ting, Liu, Yi, Yang, Jia Yao, Shi, Zhaohong
• Format: Article
• Language: English
• Subjects: bevacizumab biosimilar; Biological products; Cancer therapies; Chemotherapy; Colorectal cancer; Cost control; endoscopic mucosal resection; Ethics; Fatalities; Medical prognosis; Observational studies; Patients; Pharmacokinetics; Response rates; Review; Systematic review; Thromboembolism; Vascular endothelial growth factor; wound complications; Wound healing; wounds management
• ISSN: 1742-4801; 1742-481X; 1742-481X
• DOI: 10.1111/iwj.14638

Complications related to wound healing pose substantial obstacle in the management of colorectal cancer (CRC), specifically in the field of anorectal medicine. Biosimilars of bevacizumab have emerged as crucial therapeutic agents in the management of these complications. With the particular emphasis on effects of Bevacizumab Biosimilar Plus on wound healing among patients diagnosed with CRC, this review underscores the potential of this anorectal medication to improve patient outcomes and was aimed to assess the safety and efficacy of Bevacizumab Biosimilar Plus in relation to complications associated with wound healing in patients with CRC. The assessment centers on its therapeutic potential and safety profile within the domain of anorectal medicine. In accordance with the PRISMA guidelines, a comprehensive literature search was performed, resulting in the identification of 19 pertinent studies out of an initial 918. Priority was given to assessing the safety and adverse effects of Bevacizumab Biosimilar Plus in conjunction with its effectiveness in wound healing. The extracted data comprised the following: study design, patient demographics, comprehensive treatment regimens, wound healing‐specific outcomes and adverse effects. The evaluation of study quality was conducted utilizing the instruments provided by the Cochrane Collaboration and the Newcastle‐Ottawa Scale (NOS). Bevacizumab Biosimilar Plus demonstrates efficacy in the management of wound healing complications among patients with CRC, with a safety and efficacy profile similar to that of the original Bevacizumab, according to the analysis. Notably, several studies reported improved rates of wound healing in relation to the biosimilar. The safety profiles exhibited similarities to the anticipated anti‐VEGF agent effects. In wound management, the biosimilar also demonstrated advantages in terms of prolonged efficacy. In addition, analyses of cost‐effectiveness suggested that the use of biosimilars could result in cost reductions. Bevacizumab Biosimilar Plus exhibited potential as an anorectal medication for the effective management of wound healing complications in patients with CRC. This has substantial ramifications for improving the quality of patient care, encompassing the affordability and effectiveness of treatments.